This study is testing a new way to diagnose lung cancer by looking for specific changes in your DNA, called epigenetic markers, using a blood test. Researchers will collect blood samples and review medical records over about five years to see if this "Epigenetic Signature Assay" can accurately identify lung cancer. The goal is to develop and confirm this new diagnostic tool. You might be able to join if you are 18 or older, a patient at University of Maryland Baltimore Washington Medical Center, and can speak and understand English. The study aims to enroll 750 participants, including people with lung cancer, those at risk, and healthy volunteers. The study's success will be measured by identifying a specific DNA signature related to tumors and developing and validating the technology over one to five years. The current recruitment status is unclear.

Study design

This is an observational study with a planned enrollment of 750 participants across three cohorts, each with five different patient populations.

What's involved

You will have blood samples collected during routine clinic visits, your medical records reviewed, and fill out questionnaires at different times over approximately five years.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for approximately five years, with primary endpoints measured at one and five years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.